Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Diclofensine
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Pancopride
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
AQ-13
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
MK-2206
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
ATN-161
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
9-hexadecenoic acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
2-picolinic acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Abametapir
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Prulifloxacin
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Fenbendazole
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Oxfendazole
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Corilagin
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Agaric acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Cabotegravir
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
NH125
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
CPI1062 
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
CPI1155 
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
MDR504 hACE2-Fc
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/15/2020
EY6A
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/13/2020
N3
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/11/2020